PDCD1 and non-small cell lung carcinoma: In addition, investigation of the safety and antitumor efficacy of APX005M is ongoing in melanoma patients and those with NSCLC, with the treatment applied either systemically (NCT03123783) or intratumorally (NCT02706353), in combination with PD-1 blockade.